Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 2 3Phase NA 1Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Dermatologic 1

Conditions

Head and Neck Neoplasms 3Colorectal Neoplasms 3Uterine Cervical Neoplasms 2Melanoma 2Lung Neoplasms 2Liver Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Triple Negative Breast Neoplasms 1Tobacco Use Disorder 1Squamous Cell Carcinoma of Head and Neck 1Smoking 1Sarcoma 1Recurrence 1Precancerous Conditions 1Pharyngeal Neoplasms 1Peritoneal Neoplasms 1Paranasal Sinus Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Neoplasm, Residual 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Laryngeal Neoplasms 1Glioblastoma 1Colonic Neoplasms 1Breast Neoplasms 1Biomarker Change Linked to Breast Cancer 1

Interventions

Gemcitabine 15pembrolizumab 13Doxorubicin 13Radiotherapy 12Docetaxel 9Nivolumab 8Filgrastim 7Cyclophosphamide 7pazopanib 6Ifosfamide 6130-nm albumin-bound paclitaxel 5Temozolomide 4Irinotecan 4Ipilimumab 4Imatinib Mesylate 4Albumin-Bound Paclitaxel 4talimogene laherparepvec 3surufatinib 3pegfilgrastim 3eribulin 3atezolizumab 3Vinorelbine 3Sirolimus 3Peripheral Blood Stem Cell Transplantation 3PM 01183 3Drug Therapy 3Cisplatin 3toripalimab 2spartalizumab 2selinexor 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Sarcoma × Celecoxib × Clear all
NCT02054104 2022-01-26

Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
21 enrolled 11 charts
DermatologicSarcoma

Melanoma, Sarcoma, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡